Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting a Phase 3 clinical study titled ‘A Randomized, 2-Arm, Phase 3 Study of Elranatamab (PF-06863135) Versus Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma After Undergoing Autologous Stem-Cell Transplantation.’ The study aims to assess the clinical benefits of elranatamab monotherapy compared to lenalidomide monotherapy in patients with newly diagnosed multiple myeloma post-transplant. This study is significant as it explores potential advancements in treatment options for multiple myeloma, a challenging cancer to treat.
The study tests two interventions: Elranatamab, a bispecific antibody designed to target and kill multiple myeloma cells, and Lenalidomide, an established immunomodulatory drug. Elranatamab is administered as an injection, while Lenalidomide is taken orally.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. Participants are divided into two groups to receive either Elranatamab or Lenalidomide.
The study began on March 25, 2022, with an estimated completion date in 2025. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This study update could influence Pfizer’s stock performance positively if Elranatamab shows superior results, potentially boosting investor confidence. It also places Pfizer in a competitive position within the oncology market, particularly against other companies developing treatments for multiple myeloma.
The study is ongoing, with further details available on the ClinicalTrials portal.